Tesofensine Testing
MW: 327.25 g/mol
Small-molecule SNDRI studied for obesity. Phase 3 ongoing.
What we test on Tesofensine
HPLC-UV + LC-MS; screen for related-substance impurities.
Standard GLP-1 / Metabolic Panel
- ✓RP-HPLC purity (UV 214 nm)
- ✓LC-MS/MS identity (Orbitrap)
- ✓Counter-ion / residual TFA
- ✓Water content (KF)
- ✓Endotoxin (LAL, USP <85>)
Common impurities in this category
Truncated sequences (des-Aib, des-His), deamidated isomers, free C18 diacid chain, oxidation products, and counter-ion variability (acetate vs. TFA).
Related GLP-1 / Metabolic peptides
Adipotide
2611.13 g/mol
Proapoptotic peptide targeting white-adipose vasculature.
AOD-9604
1815.08 g/mol
C-terminal hGH fragment (aa 176-191) studied for lipolysis.
Cagrilintide
~3800 g/mol
Long-acting amylin analog; commonly co-formulated with semaglutide as CagriSema.
Orforglipron
~760 g/mol
Small-molecule, oral GLP-1 receptor agonist in late-stage development.
Retatrutide
4177.63 g/mol
Triple agonist targeting GIP, GLP-1, and glucagon receptors (LY3437943). In Phase 3 for obesity.
Semaglutide
4113.58 g/mol
GLP-1 receptor agonist with extended half-life via a C18 diacid albumin-binding chain. The branded versions are Ozempic and Wegovy.